For the quarter ending 2026-03-31, RNXT made $563K in revenue. -$3,521K in net income. Net profit margin of -625.40%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 563 | 238 | 266 | 422 |
| Cost of revenue | 84 | 28 | 53 | 152 |
| Gross profit | 479 | 210 | 213 | 270 |
| Research and development | 1,228 | 1,516 | 1,685 | 1,426 |
| Selling, general and administrative | 2,720 | 2,216 | 1,728 | 1,522 |
| Total operating expenses | 3,948 | 3,732 | 3,413 | 2,948 |
| Loss from operations | -3,469 | -3,522 | -3,200 | -2,678 |
| Interest income, net | 45 | 75 | 113 | 133 |
| Change in fair value of common warrant liability | 97 | -506 | -175 | 350 |
| Total other income (expense), net | -52 | 581 | 288 | -217 |
| Net loss | -3,521 | -2,941 | -2,912 | -2,895 |
| Basic EPS | -0.09 | -0.08 | -0.08 | -0.08 |
| Diluted EPS | -0.09 | -0.08 | -0.08 | -0.08 |
| Basic Average Shares | 38,032,421 | 36,713,775 | 36,646,278 | 36,576,567 |
| Diluted Average Shares | 38,032,421 | 36,713,775 | 36,646,278 | 36,576,567 |
RenovoRx, Inc. (RNXT)
RenovoRx, Inc. (RNXT)